Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010029379 - COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES

Publication Number WO/2010/029379
Publication Date 18.03.2010
International Application No. PCT/HU2009/000082
International Filing Date 11.09.2009
IPC
C07D 209/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
10with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 237/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
02not condensed with other rings
06having three double bonds between ring members or between ring members and non-ring members
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
22Nitrogen and oxygen atoms
C07D 239/60 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
60Three or more oxygen or sulfur atoms
C07D 263/32 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
263Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
02not condensed with other rings
30having two or three double bonds between ring members or between ring members and non-ring members
32with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 317/42 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
317Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08having the hetero atoms in positions 1 and 3
10not condensed with other rings
32with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
42Halogen atoms or nitro radicals
C07D 317/48 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
317Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08having the hetero atoms in positions 1 and 3
44ortho- or peri-condensed with carbocyclic rings or ring systems
46condensed with one six-membered ring
48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
CPC
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Applicants
  • SEMMELWEIS EGYETEM [HU]/[HU] (AllExceptUS)
  • MÁTYUS, Péter [HU]/[HU] (UsOnly)
  • MAGYAR, Kálmán [HU]/[HU] (UsOnly)
  • PIHLAVISTA, Marjo [FI]/[FI] (UsOnly)
  • GYIRES, Klára [HU]/[HU] (UsOnly)
  • HAIDER, Norbert [AT]/[AT] (UsOnly)
  • WANG, Yinghua [CN]/[CN] (UsOnly)
  • WODA, Patrick [AT]/[AT] (UsOnly)
  • DUNKEL, Petra [HU]/[HU] (UsOnly)
  • TÓTH-SARUDY, Éva [HU]/[HU] (UsOnly)
  • TÚRÓS, György [HU]/[HU] (UsOnly)
Inventors
  • MÁTYUS, Péter
  • MAGYAR, Kálmán
  • PIHLAVISTA, Marjo
  • GYIRES, Klára
  • HAIDER, Norbert
  • WANG, Yinghua
  • WODA, Patrick
  • DUNKEL, Petra
  • TÓTH-SARUDY, Éva
  • TÚRÓS, György
Agents
  • DANUBIA PATENT & LAW OFFICE LLC
Priority Data
P080056311.09.2008HU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES
(FR) COMPOSÉS POUR INHIBER L’AMINE OXYDASE SENSIBLE À LA SEMI-CARBAZIDE (SSAO) / PROTÉINE D’ADHÉSION VASCULAIRE 1 (VAP-1) ET UTILISATIONS DE CEUX-CI POUR LE TRAITEMENT ET LA PRÉVENTION DE MALADIES
Abstract
(EN) The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO/VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.
(FR) La présente invention concerne des composés de formule générale (i) ayant un fragment oxime ou un sel pharmaceutiquement acceptable, un hydrate ou un solvate de ceux-ci et leur utilisation pour inhiber l’amine oxydase sensible à la semi-carbazide (SSAO), également appelée protéine d’adhésion vasculaire 1 (VAP-1), une composition pharmaceutique comprenant le composé ou un sel, un hydrate ou un solvate de celui-ci en tant que substance active, et un procédé pour la prévention ou le traitement d’une maladie associée à SSAO/VAP-1, lesdites maladies comprenant des maladies inflammatoires aiguës ou chroniques, des maladies associées au métabolisme des glucides, des complications associées au diabète, la rétinopathie diabétique et l’œdème maculaire, des maladies associées à des dysfonctionnements des adipocytes ou des muscles lisses, des maladies neurodégénératives et des maladies vasculaires.
Related patent documents
Latest bibliographic data on file with the International Bureau